Best of ASCO - 2014 Annual Meeting

 

Welcome

Bladder Cancer

Genitourinary (Nonprostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.

Jeffrey S. Ross

4531

A novel, robust multiplex urine-based immunoassay for bladder cancer detection.

Hideki Furuya

4537

A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).

Matt D. Galsky

TPS4588

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Thomas Powles

4506

A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.

Daniel E. Castellano

TPS4593

A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.

Jianjun Gao

e16524

A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).

Nobuaki Matsubara

4542

Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).

Petros Grivas

4540

Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

Arjun Vasant Balar

4523

Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Jean H. Hoffman-Censits

4529

ATLAS: A phase 2, open-label study of rucaparib in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Petros Grivas

TPS4592

Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations.

Gregory M. Mayhew

4538

BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

Josep Tabernero

4512

Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).

Srikala S. Sridhar

4505

Cell free (cf) DNA as a tumor marker in transitional cell cancer (TCC): Monitoring response to checkpoint inhibitor (CPI) therapy.

Nicholas J. Vogelzang

e16522

Cell free (cf)DNA as a tumor marker in transitional cell carcinoma (TCC).

Mohamed Azab

e16514

Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).

Rosa Nadal

4528

Clinical validation of an ultra-deep next generation DNA sequencing approach for the detection of bladder cancer in the urine.

Jason Ablat

e16515

Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.

Mamta Parikh

4541

Comprehensive genomic characterization of urothelial carcinomas.

Amin Nassar

4527

Conservative management following clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: Contemporary outcomes of a multi-institutional prospective cohort study.

Patrick M Mazza

4522

Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC).

Vadim S. Koshkin

4546

Correlation of CD8 lymphocytes in tumors and nonsynonymous mutational load with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

Boya Deng

e16529

Determinants of guideline-based treatment in patients with cT1 bladder cancer.

Ashwin Balakrishnan

e16518

Differential expression of SRSF2 contribute to the splicing changes related to micropapillary variant histology in nonmuscle-invasive bladder cancer (NMIBC).

Adria Closa

e16520

Does neoadjuvant chemotherapy affect postoperative complication rates in elderly patients treated with radical cystectomy for bladder cancer?

Nozomi Hayakawa

e16526

Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC).

Chelsea K. Osterman

4545

Endogenous DNA damage in peripheral blood lymphocytes (PBLs) in patients with metastatic urothelial carcinoma (MUC).

Patrik Palacka

e16511

EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.

Jonathan E. Rosenberg

TPS4590

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

Joaquim Bellmunt

4534

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).

Arlene O. Siefker-Radtke

4503

First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).

Xiao X. Wei

e16517

Identification of gene expression determinants of radiosensitivity in bladder cancer (BC) cell lines.

Jasmine Pettiford

e16507

Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).

Tian Zhang

4533

IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Matt D. Galsky

TPS4589

Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder.

Sarmad Sadeghi

e16513

Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.

Amin Nassar

4539

Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).

Kristen A Batich

e16519

Neoadjuvant chemotherapy (NAC) with dose-dense gemcitabine/cisplatin (DDGC) in localized muscle-invasive bladder cancer (MIBC).

George Tsironis

e16527

Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.

Magda Zajac

4530

Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.

Peter H. O'Donnell

4532

Patterns of metastases, treatment (tx), and outcomes in bone predominant (BP) metastatic urothelial carcinoma (mUC).

Ariel Ann Nelson

e16523

PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

Andrea Necchi

TPS4595

Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.

Thomas Powles

TPS4586

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

Yves Fradet

4521

Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.

Arjun Vasant Balar

TPS4587

Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.

Alejo Rodriguez Vida

TPS4591

Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).

Jacob Adashek

4543

Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

Xinan Sheng

e16505

Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.

Andrea Necchi

4507

Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.

Robert John Corona

e16530

Prognostic value of genomic alterations of DNA repair genes in advanced bladder cancer (ABC).

Ming Yin

4536

Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study.

Carlo Cattrini

e16506

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.

Ronald De Wit

4526

Real life outcomes of metastatic urothelial carcinoma (mUC) patients treated post first line platinum based systemic therapy: A single centre experience.

Jamila Jama Almi Rir Omar

e16500

Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design.

Marco Bandini

4535

Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway.

Markus Joerger

4513

Small cell carcinoma of the urinary bladder, a single institution experience.

Gurleen Pasricha

e16512

SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US.

Gurjyot K. Doshi

4544

SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

Simon J. Crabb

TPS4594

Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy.

Neda Hashemi-Sadraei

e16525

The impact of BMI on post-operative survival in bladder cancer patients.

Gray Jodon

e16501

The preliminary study for safety of acrinol, as a novel dye, which can be used to visualize cancer nuclei of bladder urothelial carcinoma, for probe-based confocal laser endomicroscopy.

Yoshio Naya

e16510

Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).

Diogo Assed Bastos

e16516

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

Jacqueline Vuky

4524

Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

Jonathan E. Rosenberg

4504

Upper tract urothelial carcinoma is non-basal and T-cell depleted.

Panagiotis J. Vlachostergios

4525